Veradermics, Incorporated (MANE) Stock

Veradermics, Incorporated (MANE) is a Healthcare stock trading at $98.52 (as of 2026-09-02), with a market capitalization of $4.12B. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Veradermics, Incorporated is a biopharmaceutical company developing treatments for dermatologic and aesthetic conditions, including therapies for pattern hair loss and other skin conditions such as alopecia areata and common warts. Its pipeline includes oral and dissolvable microarray patch approaches aimed at use by healthcare providers and the clinical research community.

Understand Veradermics, Incorporated: how it makes money

Veradermics develops an oral, non-hormonal drug (VDPHL01) for chronic pattern hair loss in men and women, plus a small patch-based pipeline for warts and alopecia; it has no product revenue today. The investment case is a single binary event: Phase 3 approval of that one drug, with no commercial base to steady the stock in the interim.

Until VDPHL01 clears FDA review the company has zero revenue and no profit engine; every dollar of equity value is a probability-weighted option on one regulatory decision.

Business quality (Unprofitable): Pre-revenue Phase 3 biotech with no commercial operations, a single lead asset, and a cost structure (operating margin of -611%) that depends entirely on external financing until approval.

Bull case

Strong efficacy separation from placebo: 62.9% of twice-daily VDPHL01 patients reported improved or much improved AAIRS versus 13.4% on placebo at Month 6, a roughly fivefold margin that underpins a credible FDA efficacy claim.
Oral non-hormoral targets broad market: The lead program is an oral, non-hormonal option for both men and women with chronic PHL, backed by a 1,000-male-participant Phase 3 enrollment across Studies 302 and 304, addressing a market where current drugs carry hormonal side effects or topical adherence barriers.

Bear case

Deep cash burn with zero revenue: With no product sales and an operating margin of -611%, every dollar of R&D and overhead is funded by equity issuance or partnerships, creating continuous dilution pressure on existing shareholders until a commercial product exists.
Single-asset binary risk: The entire company value rests on one drug for one indication. If VDPHL01 fails its end-of-Phase 3 or FDA review, the remaining pipeline items (warts patch, alopecia patch, molluscum) are early-stage and unproven, leaving no commercial fallback to sustain the business.

Valuation — source: SEC EDGAR (first-party)
Price	$98.52
Market Cap	$4.12B
Price / Book	5.06
Price / Sales	520.77
FCF Yield	-1.7%

Profitability & Growth — source: SEC EDGAR
Revenue (TTM)	$1.56M
Net Margin	-4481.1%
Revenue Growth (YoY)	4597.1%
EPS Growth (YoY)	-97.6%
FCF Growth (YoY)	23.1%

Financial Health — source: SEC EDGAR
Altman Z-Score	6.43 (safe)

Valuation vs Sector & Industry
Sector P/E (Healthcare)	21.6
Industry P/E (Pharmaceutical Products)	17.2

Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional Holder	SUVRETTA CAPITAL MANAGEMENT, LLC ($263.27M)
Institutional Holders Tracked	10

Company
Sector	Healthcare
Industry	Pharmaceutical Products
CEO	Reid Waldman
Country	US
IPO Date	2026-02-04

Related Companies (Pharmaceutical Products; 8 comparable drugmakers)

Data as of 2026-09-02.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.